SAB BIOTHERAPEUTICS, INC. Capital Expenditures
SAB BIOTHERAPEUTICS, INC. (SABS) reported Capital Expenditures of $2.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $1.59M.
- SAB BIOTHERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $983.26K.
- SAB BIOTHERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $55.38K, a 18.40% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $100.30K, a 17.58% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $933.16K, a 176.69% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $337.26K, a 71.07% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $197.15K, a 90.90% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $2.17M, a 80.20% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.57M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $983.26K 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $933.16K 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $55.38K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $155.68K derived: sum of 2 quarters · filed 2026-03-09 | $208.19K derived: sum of 3 quarters · filed 2026-03-09 | $337.26K 10-K · filed 2026-03-09 |
| 2024-09-30 | $100.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $152.81K derived: sum of 2 quarters · filed 2025-11-14 | $281.88K 10-Q · filed 2025-11-14 | $349.75K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $52.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $181.59K 10-Q · filed 2025-08-07 | $249.45K derived: sum of 3 quarters · filed 2025-08-07 | $334.75K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $129.07K 10-Q · filed 2025-05-09 | $196.94K derived: sum of 2 quarters · filed 2025-05-09 | $282.24K derived: sum of 3 quarters · filed 2025-05-09 | $304.93K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $67.86K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $153.17K derived: sum of 2 quarters · filed 2025-03-31 | $175.85K derived: sum of 3 quarters · filed 2025-03-31 | $197.15K 10-K · filed 2025-03-31 |
| 2023-09-30 | $85.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $107.99K derived: sum of 2 quarters · filed 2024-11-06 | $129.29K 10-Q · filed 2024-11-06 | $247.04K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $22.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $43.98K 10-Q · filed 2024-08-08 | $161.74K derived: sum of 3 quarters · filed 2024-08-08 | $240.24K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $21.30K 10-Q · filed 2024-05-20 | $139.05K derived: sum of 2 quarters · filed 2024-05-20 | $217.56K derived: sum of 3 quarters · filed 2024-05-20 | $830.39K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $117.75K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $196.26K derived: sum of 2 quarters · filed 2024-03-29 | $809.09K derived: sum of 3 quarters · filed 2024-03-29 | $2.17M 10-K · filed 2024-03-29 |
| 2022-09-30 | $78.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $691.34K derived: sum of 2 quarters · filed 2023-11-13 | $2.05M 10-Q · filed 2023-11-13 | $4.41M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $612.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $1.97M 10-Q · filed 2023-08-21 | $4.33M derived: sum of 3 quarters · filed 2023-08-21 | $7.56M derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | $1.36M 10-Q · filed 2023-05-15 | $3.72M derived: sum of 2 quarters · filed 2023-05-15 | $6.95M derived: sum of 3 quarters · filed 2023-05-15 | $10.41M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $2.36M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | $5.59M derived: sum of 2 quarters · filed 2023-04-28 | $9.05M derived: sum of 3 quarters · filed 2023-04-28 | $10.94M 10-K/A · filed 2023-04-28 |
| 2021-09-30 | $3.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $6.69M derived: sum of 2 quarters · filed 2022-11-14 | $8.58M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $5.35M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $1.89M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $12.73M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |